Pf-03049423

Pf-03049423

SCHEMBL29766850

CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PDE5A

The experimentally established mechanism targets of Pf-03049423. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE5A known ✓ O76074 20/20 1.00
KCNH2 Q12809 6/20 1.00
PDE6A P16499 5/20 0.70
PDE11A Q9HCR9 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pf-03049423 SCHEMBL1969224 1.00 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
Pf-03049423 SCHEMBL29357029 1.00 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
SCHEMBL1973676 0.97 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
SCHEMBL1973153 0.96 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
SCHEMBL1970086 0.93 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
SCHEMBL1971532 0.93 PDE5A (1.00) PDE5AKCNH2PDE6APDE11A
SCHEMBL1968969 0.91 PDE5A (0.84) PDE5AKCNH2PDE6APDE11A
SCHEMBL1970644 0.91 PDE5A (0.84) PDE5AKCNH2PDE6A
SCHEMBL1970611 0.91 PDE5A (1.00) PDE5AKCNH2PDE6A
SCHEMBL1970610 0.91 PDE5A (1.00) PDE5AKCNH2PDE6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220244263-A1 METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-04 US disclosed